Kyowa Kirin Co., Ltd. (TSE: 4151, President and CEO:nMasashi Miyamoto, “Kyowa Kirin”) today announces that its co-development and co-marketingnagreement with Zeria Pharmaceutical Co., Ltd.(TSE: 4559, President and COO: Mitsuhiro Ibe, Zeria Pharmaceutical) regarding ASACOL®(generic name: mesalazine), an anti-inflammatory agent used to treat ulcerative colitis in Japan, will be terminated on March 31, 2020
Zeria Pharmaceutical Employee's Death Was 'Job-Related'
Arizona-based Cancer Prevention Pharmaceuticals, Inc., a company developing therapeutics that reduce the risk of cancer, filed with the U.S. Securities and Exchange Commission to raise up to $29 million in an initial public offering, IPO Investment Manager Renaissance Capital announced this morning.